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Abstract 
We describe a 65-year-old female with relapsed ovarian cancer who developed a severe 
hypersensitivity reaction during the second cycle of carboplatin treatment. The patient 
developed respiratory failure, acute respiratory distress syndrome and hypotension, 
requiring admission to the intensive care unit. 
 
Introduction 
Carboplatin is frequently used in patients with ovarian cancer, in second-line or 
salvage settings [1]. The carboplatin-associated incidence of nephrotoxicity or 
neurotoxicity is low. Serious hypersensitivity reactions due to carboplatin have been 
previously described [2–6]. Carboplatin toxicity normally develops after more than 5 or 
6 cycles of treatment; however, previous studies were able to show that patients have 
developed toxicity during their initial therapy or during their second or third treatment 
[7]. 
Case Report 
We describe a 65-year-old patient with relapsed ovarian cancer who was treated with carboplatin 
and developed toxicity during the second cycle. The patient received a 412-mg dose of carboplatin. 
The dose was calculated using the Calvert formula. Twenty min after the infusion was started, the 
patient developed dyspnea, wheezing, hypotension and confusion. Her blood pressure was 90/40 mm 
Hg, saturation 78% in room air, pulse rate 140 bpm and breath rate 34 breaths/min. The infusion was 
stopped and our patient was transferred to the intensive care unit (ICU). She was intubated due to 
respiratory failure, and adrenaline, fluids and corticosteroids were infused. Cardiac ultrasound was 
performed and acute coronary syndrome was excluded by ECG and troponin I. 
Pulmonary embolism was ruled out by a spiral CT scan of the lungs. A Swan-Ganz catheter was 
inserted via the right subclavian vein. Pulmonary capillary wedge pressure and central venous 
pressure were 4 and 3 mm Hg, respectively. The patient was ventilated based on acute respiratory  
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distress syndrome ventilation protocol. Blood and urine cultures were negative, rapid abdomen 
ultrasound was normal and a brain CT scan was without findings. Six days after ICU admission, the 
patient developed fever and ventilator-associated pneumonia was diagnosed. Bronchoalveolar lavage 
was drawn and the patient was treated with antibiotics. Thereafter, our patient became septic and 
finally died. 
Discussion 
Carboplatin is used as a second-line drug in gynecological malignancies. Previous 
studies were able to document serious heterogeneous adverse hypersensitivity 
reactions to carboplatin administration. Toxicity due to carboplatin occurs more 
commonly after 5–6 cycles. Recent studies have suggested that reactions develop due 
to a type I response mediated by the release of histamine and cytokines as well as the 
involvement of a type IV reaction with T cell-mediated production of cytokines [8, 9]. 
Our patient developed hypotension, wheezing with respiratory failure and dyspnea 
during the second course of carboplatin administration, 20 min after the infusion was 
started. This led us to conclude that carboplatin induced a hypersensitivity reaction in 
our patient who received this drug due to a relapse of ovarian cancer. 
Cardiogenic pulmonary edema, stroke, sepsis and pulmonary embolism were 
excluded. Clinicians should be alert following the initiation of carboplatin cycles. 
Serious adverse events normally occur after 5–6 cycles but can develop earlier, during 
the first 3 treatment cycles. 
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